Substance P modulates electroacupuncture analgesia in humanized mice with sickle cell disease

• Published in: Journal of pain research Vol. 12; pp. 2419 - 2426
• Main Authors: Wang, Ying, Lei, Jianxun, Jha, Ritu K, Kiven, Stacy, Gupta, Kalpna
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.08.2019; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Acupuncture; Analgesia; Analgesics; Chronic pain; Comorbidity; EDTA; Genetic engineering; Hematology; Hemoglobin; Immunoglobulins; Immunohistochemistry; Kinases; Microscopy; Narcotics; Original Research; p38 MAPK; Pain; Pain management; Peptides; Proteins; Rodents; Sickle cell anemia; Sickle cell disease; Spinal cord; substance P; acupuncture; pain; neuroinflammation; p38 MAPK; neurokinin 1 receptor; neuromodulator
• ISSN: 1178-7090; 1178-7090
• DOI: 10.2147/JPR.S210196

Chronic pain is a major comorbidity of sickle cell disease (SCD). Acupuncture, a non-opioid and non-addictive therapy to treat pain, was found to reduce pain in the majority (80%) of SCD patients in an earlier retrospective review. We observed that electroacupuncture (EA) decreased hyperalgesia in transgenic mice with SCD with varied analgesia from high to moderate to no response. Interestingly, poor responders exhibited high levels of substance P (SP), a mediator of chronic pain, as well as active p38 MAPK in spinal cords. The present study aimed to investigate the roles of inhibition of SP and SP-activated p38 MAPK in chronic pain in sickle mice that are poorly responsive to EA intervention (moderate/non-responders). Humanized mouse model with SCD defined as moderate- and non-responders to EA were intraperitoneally administered with antagonist of SP receptor NK1R (netupitant, 10 mg/kg/day, i.p.) or p38 MAPK inhibitor (SB203580, 10 mg/kg/day, i.p.) alone or in combination with EA (acupoint GB30, every 3rd day until day 12). Hyperalgesia to mechanical, thermal and cold stimuli, as well as deep tissue were measured. Phosphorylated p38 MAPK (phospho-p38 MAPK) in the lumbar spinal cord was quantified using western blotting. Phospho-p38 MAPK nuclear translocation in spinal dorsal horn was examined using immunohistochemical staining and confocal microscopy. In EA poor-responders, combined treatment with EA and netupitant significantly enhanced the analgesic effects of EA in poor-responders on mechanical, heat, cold, and deep tissue pain, and decreased phosphorylation of p38 MAPK in lumbar spinal cords and its nuclear translocation in the spinal dorsal horn. Furthermore, combined treatment with EA and SB203580 significantly improved analgesic effects of EA on mechanical and heat hyperalgesia, but not cold or deep tissue hyperalgesia. However, additional EA treatment only, or administration of either netupitant or SB203580 alone did not lead to analgesic effects. These results suggest a pivotal role of SP in maintaining the chronic pain in SCD via spinal phospho-p38 MAPK signaling, which may hinder the effect of EA in poor responders. Inhibition of SP signaling pathway or activity of p38 MAPK significantly improved the EA analgesia In EA poor-responders with SCD, which provides a promising way to treat the chronic pain in patients with SCD.